250 related articles for article (PubMed ID: 15464535)
1. Sildenafil: emerging cardiovascular indications.
Raja SG; Nayak SH
Ann Thorac Surg; 2004 Oct; 78(4):1496-506. PubMed ID: 15464535
[TBL] [Abstract][Full Text] [Related]
2. Type 5 phosphodiesterase inhibitors in the treatment of erectile dysfunction and cardiovascular disease.
Ravipati G; McClung JA; Aronow WS; Peterson SJ; Frishman WH
Cardiol Rev; 2007; 15(2):76-86. PubMed ID: 17303994
[TBL] [Abstract][Full Text] [Related]
3. Therapeutic potential of phosphodiesterase 5 inhibition for cardiovascular disease.
Reffelmann T; Kloner RA
Circulation; 2003 Jul; 108(2):239-44. PubMed ID: 12860892
[No Abstract] [Full Text] [Related]
4. Long-term treatment with oral sildenafil is safe and improves functional capacity and hemodynamics in patients with pulmonary arterial hypertension.
Michelakis ED; Tymchak W; Noga M; Webster L; Wu XC; Lien D; Wang SH; Modry D; Archer SL
Circulation; 2003 Oct; 108(17):2066-9. PubMed ID: 14568893
[TBL] [Abstract][Full Text] [Related]
5. [Therapy of erectile dysfunction. Hard facts support sildenafil].
MMW Fortschr Med; 2003 Sep; 145(35-36):50-1. PubMed ID: 14584211
[No Abstract] [Full Text] [Related]
6. [Comparison of efficacy and safety of phosphodiesterase type 5 inhibitors in the treatment of erectile dysfunction].
Chen Q; Wang N; Yao F; Lu X
Zhonghua Nan Ke Xue; 2004 Apr; 10(4):302-4. PubMed ID: 15148932
[TBL] [Abstract][Full Text] [Related]
7. Differences in hemodynamic and oxygenation responses to three different phosphodiesterase-5 inhibitors in patients with pulmonary arterial hypertension: a randomized prospective study.
Ghofrani HA; Voswinckel R; Reichenberger F; Olschewski H; Haredza P; Karadaş B; Schermuly RT; Weissmann N; Seeger W; Grimminger F
J Am Coll Cardiol; 2004 Oct; 44(7):1488-96. PubMed ID: 15464333
[TBL] [Abstract][Full Text] [Related]
8. Cardioprotection with phosphodiesterase-5 inhibition--a novel preconditioning strategy.
Kukreja RC; Ockaili R; Salloum F; Yin C; Hawkins J; Das A; Xi L
J Mol Cell Cardiol; 2004 Feb; 36(2):165-73. PubMed ID: 14871543
[TBL] [Abstract][Full Text] [Related]
9. Intravenous sildenafil is a potent pulmonary vasodilator in children with congenital heart disease.
Schulze-Neick I; Hartenstein P; Li J; Stiller B; Nagdyman N; Hübler M; Butrous G; Petros A; Lange P; Redington AN
Circulation; 2003 Sep; 108 Suppl 1():II167-73. PubMed ID: 12970227
[TBL] [Abstract][Full Text] [Related]
10. The phosphodiesterase 5 inhibitor sildenafil has no effect on cerebral blood flow or blood velocity, but nevertheless induces headache in healthy subjects.
Kruuse C; Thomsen LL; Jacobsen TB; Olesen J
J Cereb Blood Flow Metab; 2002 Sep; 22(9):1124-31. PubMed ID: 12218418
[TBL] [Abstract][Full Text] [Related]
11. Sildenafil increases cerebrovascular reactivity: a transcranial Doppler study.
Brenner S
Neurology; 2006 May; 66(9):1455-6; author reply 1455-6. PubMed ID: 16682690
[No Abstract] [Full Text] [Related]
12. [Treatment of pulmonary arterial hypertension: phosphodiesterase-5 inhibitors].
Ghofrani HA; Grimminger F
Dtsch Med Wochenschr; 2006 Dec; 131(49 Suppl 9):S311-4. PubMed ID: 17139594
[TBL] [Abstract][Full Text] [Related]
13. The effects of phosphodiesterase-5 inhibition with sildenafil on pulmonary hemodynamics and diffusion capacity, exercise ventilatory efficiency, and oxygen uptake kinetics in chronic heart failure.
Guazzi M; Tumminello G; Di Marco F; Fiorentini C; Guazzi MD
J Am Coll Cardiol; 2004 Dec; 44(12):2339-48. PubMed ID: 15607396
[TBL] [Abstract][Full Text] [Related]
14. Pharmacological preconditioning with sildenafil: Basic mechanisms and clinical implications.
Kukreja RC; Salloum F; Das A; Ockaili R; Yin C; Bremer YA; Fisher PW; Wittkamp M; Hawkins J; Chou E; Kukreja AK; Wang X; Marwaha VR; Xi L
Vascul Pharmacol; 2005; 42(5-6):219-32. PubMed ID: 15922255
[TBL] [Abstract][Full Text] [Related]
15. Phosphodiesterase 5 inhibition: effects on the coronary vasculature.
Jackson G
Int J Clin Pract; 2001 Apr; 55(3):183-8. PubMed ID: 11351772
[TBL] [Abstract][Full Text] [Related]
16. Non erectile dysfunction application of sildenafil.
Cremers B; Böhm M
Herz; 2003 Jun; 28(4):325-33. PubMed ID: 12825148
[TBL] [Abstract][Full Text] [Related]
17. Phosphodiesterase 5 inhibitors for erectile dysfunction.
Setter SM; Iltz JL; Fincham JE; Campbell RK; Baker DE
Ann Pharmacother; 2005; 39(7-8):1286-95. PubMed ID: 15941818
[TBL] [Abstract][Full Text] [Related]
18. Pharmacology and drug interaction effects of the phosphodiesterase 5 inhibitors: focus on alpha-blocker interactions.
Kloner RA
Am J Cardiol; 2005 Dec; 96(12B):42M-46M. PubMed ID: 16387566
[TBL] [Abstract][Full Text] [Related]
19. Phosphodiesterase 5 inhibition in chronic heart failure and pulmonary hypertension.
Patel MD; Katz SD
Am J Cardiol; 2005 Dec; 96(12B):47M-51M. PubMed ID: 16387567
[TBL] [Abstract][Full Text] [Related]
20. Effects of a new phosphodiesterase enzyme type V inhibitor (UK 343-664) versus milrinone in a porcine model of acute pulmonary hypertension.
Urdaneta F; Willert JL; Beaver T; Naik B; Kirby DS; Lobato EB
Ann Thorac Surg; 2004 Oct; 78(4):1433-7. PubMed ID: 15464509
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
